EZH2 is a potential therapeutic target for H3K27M mutant paediatric gliomas
Direct links to NCBI, no account and no request form: the whole study as GSE85390_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 38 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA338311 and SRA study SRP081168. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Sort into groups and it will be fetched from NCBI.
+ 38 more — browse all 38 samples with per-sample file links →
- GSE298719 A Human Single-cell Atlas Identifies OLR1+ Scar-associated Macrophages as a Therapeutic Target for Chronic Liver Disease 41 samples
- GSE260997 Mutant IDH inhibitors induce lineage differentiation in IDH-mutant Oligodendroglioma III 2458 samples
- GSE270550 Mutant CEBPA promotes tolerance to inflammatory stress through deficient AP-1 activation [RNA-Seq] 75 samples
- GSE45982 EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation 61 samples
- GSE266956 Increased translation driven by a non-canonical EZH2 cistrome creates a synthetic vulnerability in enzalutamide-resistant prostate cancer 42 samples
- GSE271616 A STAT5B-driven mouse model of hepatosplenic γδ T cell lymphoma reveals therapeutic efficacy of JAK inhibitors 23 samples
- GSE261915 Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells 21 samples
- GSE324714 Acquired genetic and cell state changes in IDH-mutant glioma progression [coculture experiments] 16 samples
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.